Effect of hepatic cytochrome P450 oxidoreductase deficiency on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-DNA adduct formation in P450 reductase conditional null mice.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsArlt, Volker M.
Gamboa da Costa, Goncalo
Evans, James D.
Farmer, Peter B.
Wolf, C. Roland
Henderson, Colin J.
Phillips, David H.
MetadataShow full item record
Abstract2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), formed during the cooking of foods, induces colon cancer in rodents. PhIP is metabolically activated by cytochrome P450s (CYPs). In order to evaluate the role of hepatic CYPs in the bioactivation of PhIP, we used Reductase Conditional Null (RCN) mice, in which cytochrome P450 oxidoreductase (POR), the unique electron donor to CYPs, can be specifically deleted in hepatocytes by pretreatment with 3-methylcholanthrene (3-MC), resulting in the loss of essentially all hepatic CYP function. RCN mice were treated orally with 50 mg/kg body weight PhIP daily for 5 days, with and without 3-MC pretreatment. PhIP-DNA adducts (i.e. N-(deoxyguanosin-8-yl)-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine [dG-C8-PhIP]), measured by liquid chromatography-tandem mass spectrometry, were highest in colon (1362 adducts per 10(8) deoxynucleosides), while adduct levels in liver were ~3.5-fold lower. While no differences in PhIP-DNA adduct levels were found in livers with active POR versus inactivated POR, adduct levels were on average ~2-fold lower in extra-hepatic tissues of mice lacking hepatic POR. Hepatic microsomes from RCN mice with or without 3-MC pretreatment were also incubated with PhIP and DNA in vitro. PhIP-DNA adduct formation was ~8-fold lower with hepatic microsomes from POR-inactivated mice than with those with active POR. Most of the hepatic microsomal activation of PhIP in vitro was attributable to CYP1A. Our results show that PhIP-DNA adduct formation in colon involves hepatic N-oxidation, circulation of activated metabolites via the bloodstream to extra-hepatic tissues and further activation resulting in the formation of dG-C8-PhIP. Besides hepatic CYPs, PhIP may be metabolically activated mainly by a non-CYP pathway in liver.
CitationDrug Metab. Dispos. 2011, 39 (12):2169-2173
JournalDrug Metabolism and Disposition
SponsorsThis work was supported by Environmental Cancer Risk, Nutrition and Individual Susceptibility (ECNIS) as part of the European Union 6 th Framework, Priority 5: ‘Food Quality and Safety’ [Contract No. 513943]; Cancer Research UK; and the Grant Agency of the Czech Republic [Grant P301/10/0356]
- Metabolic activation of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine and DNA adduct formation depends on p53: Studies in Trp53(+/+),Trp53(+/-) and Trp53(-/-) mice.
- Authors: Krais AM, Speksnijder EN, Melis JP, Singh R, Caldwell A, Gamboa da Costa G, Luijten M, Phillips DH, Arlt VM
- Issue date: 2016 Feb 15
- Detection and quantitation of N-(deoxyguanosin-8-yl)-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine adducts in DNA using online column-switching liquid chromatography tandem mass spectrometry.
- Authors: Singh R, Arlt VM, Henderson CJ, Phillips DH, Farmer PB, Gamboa da Costa G
- Issue date: 2010 Aug 1
- Cytochrome b <sub>5</sub> impacts on cytochrome P450-mediated metabolism of benzo[a]pyrene and its DNA adduct formation: studies in hepatic cytochrome b <sub>5</sub> /P450 reductase null (HBRN) mice.
- Authors: Reed L, Mrizova I, Barta F, Indra R, Moserova M, Kopka K, Schmeiser HH, Wolf CR, Henderson CJ, Stiborova M, Phillips DH, Arlt VM
- Issue date: 2018 Apr
- Exposure to benzo[a]pyrene of Hepatic Cytochrome P450 Reductase Null (HRN) and P450 Reductase Conditional Null (RCN) mice: Detection of benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and 32P-postlabelling.
- Authors: Arlt VM, Poirier MC, Sykes SE, John K, Moserova M, Stiborova M, Wolf CR, Henderson CJ, Phillips DH
- Issue date: 2012 Sep 3
- Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
- Authors: Stiborová M, Arlt VM, Henderson CJ, Wolf CR, Kotrbová V, Moserová M, Hudecek J, Phillips DH, Frei E
- Issue date: 2008 Feb 1